Try Corel software for free. No risk. No obligation. No credit card required!
If you’d like, I can:
: Designed for slow release and localized action within the oral cavity or absorption across the oral mucosa. These cross-reference with Ph. Eur. Monograph Oromucosal Preparations (1807) . 3. Production and Manufacturing Standards
Note: This standard explicitly excludes lozenges, chewable oral pastes, or tablets intended for alternative routes like implants or vaginal insertion, which are covered by separate dedicated monographs. Production and Manufacturing Controls
The , titled Tablets (Compressi) , is a legally binding general monograph that establishes essential quality standards for tablet dosage forms in Europe. As a "general monograph," it provides overarching requirements for production, testing, and labeling that apply to all tablets, unless a specific monograph for a particular drug provides different instructions. Scope and Definition
Monograph 0478 begins by establishing a clear, foundational understanding of what a tablet is and, just as importantly, what it is not. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
A significant portion of the monograph is dedicated to the . Many tablets bear break marks (or break-marks) to allow them to be split, either to ease intake or to deliver fractional doses. However, the monograph makes a crucial distinction:
While not always mandatory for final release, tests for Friability (2.9.7) and Resistance to Crushing (2.9.8) are used during production to ensure tablets don't crumble during handling. Recent Regulatory Updates
The provides the essential quality standards and legal requirements for Tablets (Compressi) within the European regulatory framework. Managed by the European Directorate for the Quality of Medicines & HealthCare (EDQM) , this monograph ensures that solid oral dosage forms are safe, effective, and consistent across all signatory states. Definition and Scope of Monograph 0478
The monograph dictates that the excipients used must be safe, non-toxic, and must not adversely affect the therapeutic efficacy or bioavailability of the active pharmaceutical ingredient (API). Excipients typically include diluents, binders, disintegrants, glidants, lubricants, and coloring or flavoring agents. Minimizing Microbial Contamination If you’d like, I can: : Designed for
Often colloquially referred to as "hardness" testing, this evaluates the diametral force required to crush the tablet. While the monograph requires manufacturers to measure this property to ensure structural integrity, specific numerical limits are usually defined in the individual substance monographs rather than the general 0478 text. 4. Specific Requirements by Tablet Type
While it primarily covers standard oral tablets, the monograph explicitly segmentizes several distinct categories of tablets, each with tailored criteria:
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Revised Ph. Eur. Chapter Tablets - ECA Academy
Monograph 0478 applies specifically to . These are obtained by compressing uniform volumes of particles or particle aggregates generated through granulation methods. Exclusions and Boundaries Monograph Oromucosal Preparations (1807)
The monograph distinguishes several categories of tablets based on their intended use or design. A summary of these categories, their definitions, and key considerations is provided in the table below:
: A critical test that measures how the active substance is released into a liquid medium over time. Ph. Eur. 0478 mandates a suitable dissolution test unless a disintegration test is otherwise justified. Disintegration (2.9.1)
The container label must include (per Ph. Eur. general notices and individual monograph):
When a tablet features a break-mark (score line) meant for dose subdivision, the manufacturer must validate that the split parts remain uniform. According to the standard test protocol: The Ph.Eur. approach to tablet splitting